Scarica l'app Stockscreener
2.12
98.13%
1.05
Dopo l'orario di chiusura:
1.95
-0.17
-8.02%
Precedente Chiudi:
$1.07
Aprire:
$1.795
Volume 24 ore:
238.77M
Relative Volume:
58.47
Capitalizzazione di mercato:
$9.54M
Reddito:
$6.78M
Utile/perdita netta:
$-14.74M
Rapporto P/E:
-0.1315
EPS:
-16.1258
Flusso di cassa netto:
$-8.51M
1 W Prestazione:
+103.85%
1M Prestazione:
+103.85%
6M Prestazione:
-73.83%
1 anno Prestazione:
-80.06%
Intervallo 1D:
$1.78
$2.73
Intervallo di 1 settimana:
$1.00
$2.73
Portata 52W:
$0.693
$46.53
Bioaffinity Technologies Inc Stock (BIAF) Company Profile
Nome
Bioaffinity Technologies Inc
Settore
Industria
Telefono
210-698-5334
Indirizzo
3300 NACOGDOCHES ROAD, SAN ANTONIO
Compare BIAF vs TMO, DHR, IDXX, A, WAT
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
BIAF
Bioaffinity Technologies Inc
|
2.12 | 9.54M | 6.78M | -14.74M | -8.51M | -16.13 |
|
TMO
Thermo Fisher Scientific Inc
|
464.37 | 172.51B | 44.56B | 6.72B | 6.29B | 17.74 |
|
DHR
Danaher Corp
|
187.32 | 132.46B | 24.57B | 3.60B | 5.26B | 5.051 |
|
IDXX
Idexx Laboratories Inc
|
573.82 | 45.69B | 4.30B | 1.06B | 1.04B | 13.08 |
|
A
Agilent Technologies Inc
|
111.51 | 31.51B | 7.07B | 1.29B | 993.00M | 4.5355 |
|
WAT
Waters Corp
|
286.57 | 28.11B | 3.17B | 642.63M | 516.49M | 10.77 |
Bioaffinity Technologies Inc Borsa (BIAF) Ultime notizie
Biotech Stocks To Watch NowMarch 14th - MarketBeat
BioAffinity Technologies Projects Strong Growth Amid Market Fluctuations - timothysykes.com
bioAffinity Technologies reports 2025 financial results - Investing.com India
Crude Oil Gains Over 1%; VEON Shares Spike Higher - Benzinga
bioAffinity Technologies reports 2025 financial results By Investing.com - Investing.com Nigeria
bioAffinity Technologies Expands Lung Cancer Detection Initiatives - StocksToTrade
bioAffinity Technologies jumps 124% as it touts record 2025 CyPath Lung growth and outlines expansion plans - Quiver Quantitative
bioAffinity Technologies Stock Soars 120% On CyPath Lung Sales Growth - Benzinga
BioAffinity Technologies Shakes Up Diagnostics Field with Innovative Clinical Initiatives - timothysykes.com
Dow Gains Over 300 Points; US GDP Growth Revised Lower In Q4 - Benzinga
BIAF: CyPath® Lung test sales surged 99% in 2025, driving record revenue and future growth momentum - TradingView
BioAffinity Technologies, Inc. Reports Earnings Results for the Full Year Ended December 31, 2025 - marketscreener.com
CyPath Lung growth accelerates while bioAffinity (NASDAQ: BIAF) posts larger 2025 loss - Stock Titan
12 Health Care Stocks Moving In Friday's Pre-Market Session - Benzinga
bioAffinity Technologies Announces Record 2025 Revenue and Unit Sales for Flagship Lung Cancer Diagnostic CyPath® Lung - itemonline.com
BIAF vs. GH: Which cancer detection stock is the better buy now? - MSN
bioAffinity launches 2,000-patient study for noninvasive lung cancer test - Mugglehead Investment Magazine
Volume Recap: Can bioAffinity Technologies Inc lead its sector in growth2026 Macro Moves & Daily Stock Momentum Reports - baoquankhu1.vn
BioAffinity launches large-scale clinical study for lung cancer detection technology - MSN
Study Begins for bioAffinity Technologies’ CyPath Lung Cancer Diagnostic - Medical Product Outsourcing
CyPath Lung Expands Diagnostic Capabilities as bioAffinity Grows Board - StocksToTrade
bioAffinity Technologies Announces Initiation of Large-Scale Longitudinal Clinical Study for Its Non - pharmiweb.com
bioAffinity Launches Major Lung Cancer Detection Study - TipRanks
BioAffinity Technologies initiates clinical study for CyPath Lung - TipRanks
bioAffinity Technologies Announces Initiation of Large-Scale Longitudinal Clinical Study for Its Noninvasive CyPath® Lung Cancer Diagnostic - The Joplin Globe
Aug Ideas: Will bioAffinity Technologies Inc. Equity Warrant stock split attract more investorsJuly 2025 Final Week & Fast Entry Momentum Trade Alerts - Naître et grandir
bioAffinity Announces Upcoming Departure of Two Board Directors - TipRanks
BIAF vs. GH: Which Cancer Detection Stock Is the Better Buy Now? - Finviz
bioAffinity Technologies, Inc. (BIAFW) Competitors - Meyka
bioAffinity presents asthma therapy matching research at AAAAI - Investing.com
bioAffinity Showcases Sputum-Based Platform for Personalized Asthma Care - TipRanks
bioAffinity presents asthma therapy matching research at AAAAI By Investing.com - Investing.com Australia
Clinical Utility of bioAffinity Technologies’ CyPath® Lung Test Demonstrated in Real-World Case Study - mx.advfn.com
bioAffinity presents poster showing sputum test can ID receptors for leading asthma biologics - TradingView
bioAffinity Technologies (NASDAQ: BIAF) shows asthma and COPD diagnostic data - Stock Titan
bioAffinity Technologies Presents Positive Research Findings for its Novel Diagnostic Platform Technology to Identify Optimal Therapies for Asthma Patients - ChartMill
BIAFW Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Is bioAffinity Technologies Inc. affected by consumer sentimentJuly 2025 Recap & Safe Capital Growth Tips - mfd.ru
Is bioAffinity Technologies Inc stock heavily shorted2025 Geopolitical Influence & Verified Swing Trading Watchlists - baoquankhu1.vn
bioAffinity Technologies, Inc.Common Stock (NQ: BIAF - The Chronicle-Journal
12 Health Care Stocks Moving In Thursday's After-Market Session - Benzinga
bioAffinity launches study to test lung cancer diagnostic By Investing.com - Investing.com Australia
bioAffinity Technologies Announces Validation Study with Brooke Army Medical Center to Expand Sample Collection Options for the CyPath® Lung Noninvasive Early Detection Lung Cancer Test - BioSpace
bioAffinity launches study to test lung cancer diagnostic - Investing.com
bioAffinity Technologies Announces Validation Study with Brooke Army Medical Center to Expand Sample - PharmiWeb.com
bioAffinity Launches New CyPath Lung Validation Study - TipRanks
Bioaffinity announces validation study for lung cancer test - marketscreener.com
New CyPath Lung validation study at BAMC by bioAffinity (BIAF) - Stock Titan
bioAffinity Adjourns Special Stockholder Meeting for Lack Quorum - MSN
bioAffinity Technologies (NASDAQ:BIAF) Stock Price Down 13.8% – Here’s What Happened - Defense World
Buyback Watch: Is bioAffinity Technologies Inc Equity Warrant stock overvalued or fairly pricedNew Guidance & Technical Pattern Based Buy Signals - baoquankhu1.vn
Bioaffinity Technologies Inc Azioni (BIAF) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.34%
0.59%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):